Safety, Tolerability, and Pharmacokinetics of SAB-301 in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

May 28, 2016

Primary Completion Date

April 10, 2018

Study Completion Date

April 30, 2018

Conditions
Middle East Respiratory Syndrome Coronavirus
Interventions
BIOLOGICAL

SAB-301

SAB-301 is a purified human immune globulin G (hIgG) polyclonal antibody designed to specifically bind to the MERS-CoV spike (S) protein, a component of the virion membrane that is responsible for binding of the virus to the host cell. The hIgG is purified from the plasma of immunized transchromosomic (Tc) bovines that were immunized with a recombinant spike protein produced in insect cells. SAB-301 is purified hIgG in a sterile liquid formulated in 10 mM glutamic acid monosodium salt, 262 mM D-sorbitol, 0.05 mg/mL Tween 80, pH 5.5. The drug product will be administered intravenously and will be diluted in saline per the clinical protocol.

OTHER

Normal (9%) Saline

Normal (0.9%) saline in approximately the same volume as each cohort in the experimental drug arm.

Trial Locations (1)

20892

National Institutes of Health Clinical Center, Bethesda

Sponsors
All Listed Sponsors
collaborator

Naval Medical Research Center

FED

collaborator

SAb Biotherapeutics, Inc.

INDUSTRY

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT02788188 - Safety, Tolerability, and Pharmacokinetics of SAB-301 in Healthy Adults | Biotech Hunter | Biotech Hunter